- Home
- ESTC vs TFX Comparison
ESTC vs TFX Comparison
Compare ESTC & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESTC
- TFX
- Stock Information
- Founded
- ESTC 2012
- TFX 1943
- Country
- ESTC Netherlands
- TFX United States
- Employees
- ESTC N/A
- TFX N/A
- Industry
- ESTC Computer Software: Prepackaged Software
- TFX Medical/Dental Instruments
- Sector
- ESTC Technology
- TFX Health Care
- Exchange
- ESTC Nasdaq
- TFX Nasdaq
- Market Cap
- ESTC 8.9B
- TFX 9.0B
- IPO Year
- ESTC 2018
- TFX N/A
- Fundamental
- Price
- ESTC $88.58
- TFX $187.47
- Analyst Decision
- ESTC Buy
- TFX Buy
- Analyst Count
- ESTC 25
- TFX 9
- Target Price
- ESTC $106.61
- TFX $259.00
- AVG Volume (30 Days)
- ESTC 920.1K
- TFX 531.9K
- Earning Date
- ESTC 11-21-2024
- TFX 10-31-2024
- Dividend Yield
- ESTC N/A
- TFX 0.73%
- EPS Growth
- ESTC N/A
- TFX N/A
- EPS
- ESTC 0.58
- TFX 5.03
- Revenue
- ESTC $1,320,988,000.00
- TFX $3,025,824,000.00
- Revenue This Year
- ESTC $15.99
- TFX $4.52
- Revenue Next Year
- ESTC $14.15
- TFX $4.92
- P/E Ratio
- ESTC $153.31
- TFX $37.26
- Revenue Growth
- ESTC 18.72
- TFX 2.27
- 52 Week Low
- ESTC $69.00
- TFX $185.84
- 52 Week High
- ESTC $136.06
- TFX $257.85
- Technical
- Relative Strength Index (RSI)
- ESTC 62.21
- TFX 25.21
- Support Level
- ESTC $84.47
- TFX $189.95
- Resistance Level
- ESTC $92.60
- TFX $195.47
- Average True Range (ATR)
- ESTC 2.50
- TFX 5.55
- MACD
- ESTC 0.30
- TFX -0.70
- Stochastic Oscillator
- ESTC 69.77
- TFX 6.05
About ESTC Elastic N.V.
Elastic is a software company based in Mountain View, California, focusing on search-adjacent products. Its search engine allows it to process both structured and unstructured data while gleaning insights from that data. The firm's primary focus is on enterprise search, observability, and security.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.